Published in Blood Rev on April 01, 2012
Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood (2012) 1.51
Myelodysplastic Syndromes and Iron Chelation Therapy. Mediterr J Hematol Infect Dis (2017) 1.37
Non-transfusion-dependent thalassemias. Haematologica (2013) 1.21
β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies. Haematologica (2015) 1.06
The crossroads of iron with hypoxia and cellular metabolism. Implications in the pathobiology of pulmonary hypertension. Am J Respir Cell Mol Biol (2014) 0.98
Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol (2013) 0.95
Out of balance--systemic iron homeostasis in iron-related disorders. Nutrients (2013) 0.92
Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia trait. Blood (2014) 0.87
Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia. Blood (2014) 0.86
Use of magnetic resonance imaging to monitor iron overload. Hematol Oncol Clin North Am (2014) 0.82
Deferasirox: appraisal of safety and efficacy in long-term therapy. J Blood Med (2013) 0.80
Serum ferritin level and morbidity risk in transfusion-independent patients with β-thalassemia intermedia: the ORIENT study. Haematologica (2014) 0.80
Splenectomy improves anaemia but does not reduce iron burden in patients with haemoglobin H Constant Spring disease. Blood Transfus (2014) 0.78
Risk of erectile dysfunction in transfusion-naive thalassemia men: a nationwide population-based retrospective cohort study. Medicine (Baltimore) (2015) 0.77
Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients. Am J Hematol (2013) 0.76
An essential cell-autonomous role for hepcidin in cardiac iron homeostasis. Elife (2016) 0.75
Prevalence and Risk Factors for Complications in Patients with Nontransfusion Dependent Alpha- and Beta-Thalassemia. Anemia (2015) 0.75
When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia. Vox Sang (2014) 0.75
Body iron stores in middle-aged patients with DM and obesity. J Midlife Health (2015) 0.75
Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet (2011) 4.27
On T2* magnetic resonance and cardiac iron. Circulation (2011) 2.33
Thalassemia intermedia: revisited. Blood Cells Mol Dis (2006) 2.31
Improved R2* measurements in myocardial iron overload. J Magn Reson Imaging (2006) 2.09
Purging iron from the heart. Br J Haematol (2004) 2.07
Longitudinal analysis of heart and liver iron in thalassemia major. Blood (2008) 1.94
MRI detects myocardial iron in the human heart. Magn Reson Med (2006) 1.90
Peripheral vasoconstriction and abnormal parasympathetic response to sighs and transient hypoxia in sickle cell disease. Am J Respir Crit Care Med (2011) 1.71
Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood (2009) 1.50
A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood (2012) 1.49
Patterns of hepatic iron distribution in patients with chronically transfused thalassemia and sickle cell disease. Am J Hematol (2009) 1.48
Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol (2007) 1.45
Nutritional deficiencies in iron overloaded patients with hemoglobinopathies. Am J Hematol (2009) 1.42
R2* imaging of transfusional iron burden at 3T and comparison with 1.5T. J Magn Reson Imaging (2007) 1.38
Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia. Eur Spine J (2010) 1.36
Magnetic resonance detection of kidney iron deposition in sickle cell disease: a marker of chronic hemolysis. J Magn Reson Imaging (2008) 1.34
Thalassemia and hypercoagulability. Blood Rev (2008) 1.29
Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol (2009) 1.23
Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica (2011) 1.23
Mechanisms of tissue-iron relaxivity: nuclear magnetic resonance studies of human liver biopsy specimens. Magn Reson Med (2005) 1.22
Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study. Curr Med Res Opin (2008) 1.20
Bone disease and skeletal complications in patients with β thalassemia major. Bone (2010) 1.19
Age-related complications in treatment-naïve patients with thalassaemia intermedia. Br J Haematol (2010) 1.18
β-thalassemia intermedia: a clinical perspective. Cold Spring Harb Perspect Med (2012) 1.14
Reproducibility of carotid intima-media thickness measurements in young adults. Radiology (2008) 1.10
Relaxivity-iron calibration in hepatic iron overload: probing underlying biophysical mechanisms using a Monte Carlo model. Magn Reson Med (2010) 1.09
MR imaging of newborns by using an MR-compatible incubator with integrated radiofrequency coils: initial experience. Radiology (2004) 1.09
Spleen R2 and R2* in iron-overloaded patients with sickle cell disease and thalassemia major. J Magn Reson Imaging (2009) 1.09
Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. Blood (2013) 1.08
Cardiac abnormalities in children with sickle cell anemia. Am J Hematol (2002) 1.07
Thalidomide and thrombosis. A meta-analysis. Thromb Haemost (2007) 1.07
Pituitary iron and volume predict hypogonadism in transfusional iron overload. Am J Hematol (2011) 1.07
Total anomalous pulmonary venous return involving drainage above, below, and to the heart: a mixed bag. J Am Soc Echocardiogr (2004) 1.07
Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension. Blood (2002) 1.05
Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood (2009) 1.05
Redefining thalassemia as a hypercoagulable state. Ann N Y Acad Sci (2010) 1.04
cAMP differentially regulates gamma-globin gene expression in erythroleukemic cells and primary erythroblasts through c-Myb expression. Biochem Biophys Res Commun (2006) 1.02
A validated disease severity scoring system for adults with type 1 Gaucher disease. Genet Med (2010) 1.01
Risk factors for pulmonary hypertension in patients with β thalassemia intermedia. Eur J Intern Med (2011) 1.01
Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. Br J Haematol (2009) 1.00
Solitary mediastinal lymph node metastasis in rectosigmoid carcinoma: a case report. Cases J (2008) 1.00
Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol (2011) 0.99
The use of appropriate calibration curves corrects for systematic differences in liver R2* values measured using different software packages. Br J Haematol (2013) 0.99
History and current impact of cardiac magnetic resonance imaging on the management of iron overload. Circulation (2009) 0.97
Iron overload in β-thalassemia intermedia: an emerging concern. Curr Opin Hematol (2013) 0.96
Fetal hemoglobin levels and morbidity in untransfused patients with β-thalassemia intermedia. Blood (2011) 0.96
Systemic endothelial dysfunction in children with idiopathic pulmonary arterial hypertension correlates with disease severity. J Heart Lung Transplant (2012) 0.94
Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study. Ann Hematol (2009) 0.93
Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. Am J Hematol (2010) 0.92
Beta-thalassemia intermedia from southern Iran: IVS-II-1 (G-->A) is the prevalent thalassemia intermedia allele. Hemoglobin (2002) 0.92
Cardiac iron overload in sickle-cell disease. Am J Hematol (2014) 0.91
Pancreatic iron loading in chronically transfused sickle cell disease is lower than in thalassaemia major. Br J Haematol (2010) 0.91
Pancreatic iron stores assessed by magnetic resonance imaging (MRI) in beta thalassemic patients. Eur J Radiol (2011) 0.91
Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial. Mov Disord (2012) 0.90
Health-related quality of life in adults with transfusion-independent thalassaemia intermedia compared to regularly transfused thalassaemia major: new insights. Eur J Haematol (2011) 0.89
Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with β thalassemia intermedia. Blood Cells Mol Dis (2011) 0.89
Acute tumor lysis syndrome secondary to hydroxycarbamide in chronic myelomonocytic leukemia. Am J Hematol (2006) 0.89
Evaluation of the 5mg/g liver iron concentration threshold and its association with morbidity in patients with β-thalassemia intermedia. Blood Cells Mol Dis (2013) 0.89
Myelin deficiencies visualized in vivo: visually evoked potentials and T2-weighted magnetic resonance images of shiverer mutant and wild-type mice. J Neurosci Res (2006) 0.89
Abnormal fundus autofluorescence results of patients in long-term treatment with deferoxamine. Ophthalmology (2012) 0.89
Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease. Eur J Haematol (2009) 0.88
A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. Nephrol Dial Transplant (2013) 0.88
Challenges associated with prolonged survival of patients with thalassemia: transitioning from childhood to adulthood. Pediatrics (2008) 0.88
Thalassaemia intermedia: an update. Mediterr J Hematol Infect Dis (2009) 0.88
Non-Hodgkin disease in beta-thalassemia major. Am J Hematol (2006) 0.88
Calibration of myocardial T2 and T1 against iron concentration. J Cardiovasc Magn Reson (2014) 0.88
Insight onto the pathophysiology and clinical complications of thalassemia intermedia. Hemoglobin (2009) 0.87
Transfusion-related Plasmodium ovale malaria complicated by acute respiratory distress syndrome (ARDS) in a non-endemic country. Parasitol Int (2010) 0.87
Prevalence of factor V Leiden, prothrombin and methylene tetrahydrofolate reductase mutations in women with adverse pregnancy outcomes in Lebanon. Am J Obstet Gynecol (2006) 0.87
Pregnancy in patients with beta-thalassemia intermedia: outcome of mothers and newborns. Am J Hematol (2006) 0.87
Congenital dyserythropoietic anemia type II: molecular analysis and expression of the SEC23B gene. Orphanet J Rare Dis (2011) 0.86
Expression of the gamma-globin gene is sustained by the cAMP-dependent pathway in beta-thalassaemia. Br J Haematol (2007) 0.86
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thromb Res (2008) 0.85
Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy. Exp Hematol (2007) 0.85
Interdependence of cardiac iron and calcium in a murine model of iron overload. Transl Res (2010) 0.85
A significant proportion of thalassemia major patients have adrenal insufficiency detectable on provocative testing. J Pediatr Hematol Oncol (2015) 0.85
Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease. Blood (2010) 0.85
Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with β-thalassemia intermedia. Blood Cells Mol Dis (2012) 0.85
Genetic variability of TMPRSS6 and its association with iron deficiency anaemia. Br J Haematol (2010) 0.84
Spontaneous abdominal hematoma in a patient treated with clopidogrel and aspirin. Ann Hematol (2006) 0.84
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol (2013) 0.84
Brain magnetic resonance angiography in splenectomized adults with β-thalassemia intermedia. Eur J Haematol (2011) 0.84
Comparison of the region-based and pixel-wise methods for cardiac T2* analysis in 50 transfusion-dependent Thai thalassemia patients. J Comput Assist Tomogr (2011) 0.84
Mechanisms of renal disease in β-thalassemia. J Am Soc Nephrol (2012) 0.84
A closer look at paroxysmal nocturnal hemoglobinuria. Eur J Intern Med (2010) 0.84
Contemporary approaches to treatment of beta-thalassemia intermedia. Blood Rev (2012) 0.83
Hypercoagulability in β-thalassemia: a status quo. Expert Rev Hematol (2012) 0.83
Thalassemia and venous thromboembolism. Mediterr J Hematol Infect Dis (2011) 0.83
Patients with sickle cell anemia on simple chronic transfusion protocol show sex differences for hemodynamic and hematologic responses to transfusion. Transfusion (2012) 0.83
Hypercoagulability in non-transfusion-dependent thalassemia. Blood Rev (2012) 0.83